Welcome to our dedicated page for Maximus SEC filings (Ticker: MMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maximus, Inc. (NYSE: MMS) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Maximus is a government services and technology company that reports its results and material events through periodic and current reports, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. These documents cover topics such as segment performance across U.S. Federal Services, U.S. Services, and Outside the U.S., contract activity, capital allocation decisions, and risk disclosures.
Investors can use this page to review Maximus filings that discuss revenue drivers like clinical programs and tech-enabled service delivery, as well as information on operating margins, adjusted EBITDA, and free cash flow as described in the company’s non-GAAP reconciliations. Current reports on Form 8-K include items such as earnings releases, updates to stock purchase programs authorized by the Board of Directors, and certain leadership changes. For example, recent 8-K filings have covered financial results for specific periods, an increase to the stock purchase program authorization, and the planned resignation of a senior legal officer.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping readers understand complex sections of lengthy 10-K and 10-Q reports. Real-time updates from the SEC’s EDGAR system ensure that new Maximus filings, including Forms 3, 4, and 5 related to insider transactions, appear promptly on this page. Users can quickly identify when executives or directors report trades in MMS stock through Form 4 filings.
Whether you are looking for the latest annual report, quarterly results, details on capital deployment such as dividends and stock purchase programs, or specific 8-K disclosures about material events, this page offers a structured view of Maximus’ regulatory history, supported by AI summaries that highlight the most important information for analysis.
John T. Martinez, Chief Legal Officer of MAXIMUS, Inc. (MMS), reported a transaction dated 09/30/2025 disposing of 3,017.119 shares of common stock at $91.37 per share. The filing explains those shares were surrendered to satisfy withholding tax from the vesting of restricted stock units (RSUs). After the reported transaction the reporting person beneficially owns 15,199.192 shares, which includes 13,230.101 previously reported RSUs and accrued dividend equivalent rights with varying distribution schedules.
MAXIMUS, Inc. (MMS) filed a Form 144 notifying the proposed sale of 1,610 common shares held at Fidelity Brokerage Services with an aggregate market value of $146,284.60. The shares represent vested restricted stock acquired and paid as compensation on 09/30/2025. The filing lists approximately 56,349,629 shares outstanding for the issuer and an approximate sale date of 10/01/2025 on the NYSE. No securities were reported sold by the filer in the past three months. The notice includes the filer’s representation that they do not possess undisclosed material adverse information about the issuer.
MAXIMUS, Inc. announced an increase to its existing stock purchase program and said it intends to buy shares opportunistically in the open market, under 10b5-1 plans, or via privately negotiated transactions. The company specified the program has no set purchase amount or expiration date and may be extended, modified, suspended or discontinued at its discretion. A press release describing the increase is filed as Exhibit 99.1 to this Current Report. The filing includes standard forward-looking statements language and points investors to the company’s Annual Report for additional risk factors and disclosures.
Anne K. Altman, a director of MAXIMUS, Inc. (MMS), reported an acquisition on 08/31/2025 of dividend equivalent rights tied to previously awarded restricted stock units. The filing shows 10.491 dividend-equivalent shares were acquired at $0, and the reporting person now beneficially owns 32,055.435 shares (direct ownership). The filing explains these dividend equivalents vest proportionately with the underlying RSUs and are the economic equivalent of one share each. The form was signed by an attorney-in-fact on 09/03/2025.
Ilene Baylinson, General Manager - Health & Human at MAXIMUS, Inc. (MMS), received dividend equivalent rights on 08/31/2025 that converted to the economic equivalent of 129.906 shares of MAXIMUS common stock. These rights accrue alongside previously awarded restricted stock units and certain performance share units where performance criteria were met. Following the reported accrual, Ms. Baylinson beneficially owns 38,201.195 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing discloses a routine equity accrual tied to awards rather than an open-market trade or option exercise.
Bruce Caswell, CEO & President and a director of MAXIMUS, Inc. (MMS), reported on Form 4 that on 08/31/2025 he acquired 807.268 shares of MAXIMUS common stock as dividend equivalent rights that accrued on previously awarded restricted stock units and certain performance share units. The transaction price is reported as $0. After the transaction, he beneficially owned 237,390.466 shares, held directly. The filing was signed by an attorney-in-fact on 09/03/2025. The form explains each dividend equivalent right is the economic equivalent of one share of MAXIMUS common stock.
Theresa D. Golinvaux, Principal Accounting Officer of MAXIMUS, Inc. (MMS), reported a non‑derivative acquisition tied to dividend equivalent rights on 08/31/2025. The filing shows 33.091 dividend-equivalent shares were added (priced at $0) that relate to previously awarded restricted stock units and certain performance share units whose performance criteria were met. After this accrual, the reporting person beneficially owns 9,731.152 shares of MAXIMUS common stock. The transaction reflects compensation-related equity accruals rather than open-market trading.
Michelle Link, Chief of Human Resources and officer of MAXIMUS, Inc. (MMS), received 97.051 shares as dividend equivalent rights related to previously awarded restricted stock units and performance share units. These dividend equivalent rights are the economic equivalent of one share of MAXIMUS common stock each and vest proportionately with the underlying RSUs and vested PSUs where performance criteria were met. After the reported accrual, Ms. Link beneficially owns 28,539.482 shares of MAXIMUS common stock, held directly.
Jan Madsen, a director of MAXIMUS, Inc. (MMS), received dividend equivalent rights tied to previously awarded restricted stock units that converted into 49.475 shares on 08/31/2025 at no cash cost, increasing his reported beneficial ownership to 18,206.463 shares. The filing identifies the acquisition as dividend equivalents that vest proportionately with the underlying RSUs, rather than a market purchase. The Form 4 was signed on behalf of Madsen by an attorney-in-fact, John T Martinez, on 09/03/2025. This disclosure reflects an insider non-cash award accrual, not a cash transaction or option exercise.
Insider transaction at MAXIMUS, Inc. (MMS): On 08/31/2025 John J. Haley, a company director, reported the acquisition of 102.761 dividend-equivalent rights related to previously awarded restricted stock units, recorded at a $0 price. Following this transaction Mr. Haley is shown as beneficially owning 39,867.345 shares directly and 71,132 shares indirectly through the John J. Haley Grantor Retained Annuity Trust Seven and 32,764 shares indirectly through the John J. Haley Grantor Retained Annuity Trust Six. The filing was signed by an attorney-in-fact on 09/03/2025.